{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.7","upperLimit":"40.2","value":"27.6"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"19.2","value":"10"}]}],"title":"180 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.3","upperLimit":"48.7","value":"35.5"},{"groupId":"OG001","lowerLimit":"8.7","upperLimit":"28.5","value":"17.5"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Per National Institutes of Health (NIH) Consensus Criteria and includes organ involvement and severity, and overall global composite score (mild/moderate/severe). A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first).\n\nThe overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"180 days and 365 days post-transplant","title":"Cumulative Incidence of Chronic GVHD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}